Albumin fusion proteins

Details Albumin fusion proteins Albumin fusion proteins

2007-07-03

2007-07-03

Carlson, Karen Cochrane (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

11393893

ABSTRACT:
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

REFERENCES:
patent: 5380712 (1995-01-01), Ballance et al.
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5612196 (1997-03-01), Becquart et al.
patent: 5646012 (1997-07-01), Fleer et al.
patent: 5665863 (1997-09-01), Yeh
patent: 5668007 (1997-09-01), Spencer et al.
patent: 5766883 (1998-06-01), Ballance et al.
patent: 5876969 (1999-03-01), Fleer et al.
patent: 5959075 (1999-09-01), Lok et al.
patent: 6165470 (2000-12-01), Becquart et al.
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6300065 (2001-10-01), Kieke et al.
patent: 6514500 (2003-02-01), Bridon et al.
patent: 6583111 (2003-06-01), DiMarchi et al.
patent: 6686179 (2004-02-01), Fleer et al.
patent: 2003/0022308 (2003-01-01), Fleer et al.
patent: 2003/0036170 (2003-02-01), Fleer et al.
patent: 2003/0036171 (2003-02-01), Fleer et al.
patent: 2003/0036172 (2003-02-01), Fleer et al.
patent: 2003/0054554 (2003-03-01), Becquart et al.
patent: 2003/0082747 (2003-05-01), Fleer et al.
patent: 2003/0104578 (2003-06-01), Ballance
patent: 2003/0125247 (2003-07-01), Rosen et al.
patent: 2003/0143191 (2003-07-01), Bell et al.
patent: 2003/0171267 (2003-09-01), Rosen et al.
patent: 2003/0199043 (2003-10-01), Ballance et al.
patent: 2003/0219875 (2003-11-01), Rosen et al.
patent: 2004/0010134 (2004-01-01), Rosen et al.
patent: 2004/0018975 (2004-01-01), DiMarchi et al.
patent: 2004/0053370 (2004-03-01), Glaesner et al.
patent: 2004/0086976 (2004-05-01), Fleer et al.
patent: 2004/0086977 (2004-05-01), Fleer et al.
patent: 2004/0171123 (2004-09-01), Rosen et al.
patent: 2005/0037022 (2005-02-01), Rosen et al.
patent: 2005/0048471 (2005-03-01), Becquart et al.
patent: 2005/0100991 (2005-05-01), Rosen et al.
patent: 2005/0186664 (2005-08-01), Rosen et al.
patent: 2005/0244931 (2005-11-01), Rosen et al.
patent: 2005/0266532 (2005-12-01), Rosen et al.
patent: 2005/0266533 (2005-12-01), Ballance et al.
patent: 0 624 195 (1994-11-01), None
patent: 0 946 191 (2003-03-01), None
patent: 1 306 092 (2003-05-01), None
patent: WO 98/19698 (1998-05-01), None
patent: WO 01/77137 (2001-10-01), None
patent: WO 02/46227 (2002-06-01), None
patent: WO 03/059934 (2003-07-01), None
patent: WO 03/060071 (2003-07-01), None
patent: WO 2005/000892 (2005-01-01), None
patent: WO 2005/003296 (2005-01-01), None
patent: WO 2005/077042 (2005-08-01), None
Baggio et al. 2004. A Recombinant Human Glucagon-Like Peptide (GLP)-1-Albumin Protein (Albugon) Mimics Peptidergic Activation of GLP-1 Receptor-Dependent Pathways Coupled With Satiety, Gastrointestinal Motility, and Glucose Homeostasis. Diabetes. 53(9): 2492-2500.
U.S. Appl. No. 10/922,142, Rosen et al.
U.S. Appl. No. 09/833,111, Rosen et al.
Adelhorst, K. et al., “Structure-Activity studies of glucagon-like peptide-1,” J. Biol. Chem. 269 (9): 6275-6278 (1994).
Gallwitz, B. et al., “Structure/activity characterization of glucagon-like peptide-1,” Eur. J. Biochem. 225: 1151-1156 (1994).
Hjorth, S.A. et al., “Glucagon and glucagons-like peptide-1: selective receptor recognition via distinct peptide epitopes,” J. Biol. Chem. 269 (48): 30121-30124 (1994).
Orskov, C. et al., “Complete sequences of glucagons-like peptide-1 from human and pig small intestine,” J. Biol. Chem. 264 (22): 12826-12829 (1989).
Parker, J.C. et al., “Structure-function analysis of a series of glucagons-like peptide-1 analogs,” J. Peptide Res. 52: 398-409 (1998).
Urso, B. et al., “Differences in signaling properties of the cytoplasmis domains of the insulin receptor and insulin-like growth factor receptor in 3T3-L1 adipocytes,” J. Biol. Chem. 274(43): 30864-30873 (1999).
Yu, K. et al., “A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis,” J. Biological Chemistry, 274(2): 13733-13736 (1999).
European Search Report for Appln. No. 02799966.3-1212-US024891, Jan. 20, 2005.
International Search Report for International App. No. PCT/US02/40891 (WO 2003/060071 A3) (Apr. 21, 2003).
International Search Report for International App. No. PCT/US2002/040892 (WO 2003/059934 A3) (Feb. 26, 2004.

Affiliated with

Also associated with

Rating

Albumin fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Albumin fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Albumin fusion proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3726720